The pandemic reduced visits to specialists last year, which in turn reduced the volume of prescriptions, according to a presentation at the Academy of Managed Care Pharmacy 2021 meeting.
In 2020, COVID-19 had an impact on diagnostic visits to specialists that in turn affected the volume of pharmaceutical prescriptions, as well as the use of acute medications due to the lack of a cold and flu season.
And while Douglas M. Long, BS, MBA, vice president, Industry Relations, IQVIA, said COVID-19 will continue to have an impact on the marketplace going forward, he told the virtual audience at the Academy of Managed Care Pharmacy 2021 meeting that the effect of the pandemic will lessen, although there are a number of what he called “wildcards.”
During his annual talk on pharmaceutical marketplace trends, he said there were a billion fewer diagnosis visits that took place in 2020, and a 21% reduction in expected diagnosis visits, he said. The top 5 specialties affected were oncology, gastroenterology, dermatology, ophthalmology, and anesthesiology, as people skipped screening tests like mammograms or getting eye care.
Some specialties had what he called “moments of growth,” such as dermatology seeing a spike in visits in June and July and psychiatry jumping in August and September.
That diagnosis gap is expected to continue in 2021, although it will be a lot less—about a 12% drop in expected visits, and 288 million fewer visits than expected. Whether that creates a new baseline will depend on the continued deployment of COVID-19 vaccines as well as the country reaching herd immunity. IQVIA's chief medical officer is optimistic and thinks it is possible for that to happen by the end of the third quarter, Long said.
But those fewer visits translate into fewer prescriptions, he said—about a 3.8% drop from January 2020 to June 2021, or about 111 million, based on an average 30 days’ supply. Oncology saw 30% fewer prescriptions and drugs for pediatric indications, 45%.
The IQVIA data also looked at telehealth, which does not generate as many prescriptions, Long said. Dermatology did not compensate for the decline in in-person visits with telehealth, but other specialties, notably rheumatology and gastroenterology, did.
Pharmaceutical trends
A few of the pharmaceutical trends Long highlighted include:
Outlook for rest of 2021
Looking ahead, cost and price will be an issue for just about all stakeholders, Long said. Payers are coping with rising oncology drug costs and managing the costs of other specialty drugs. Consumers continue to face rising out-of-pocket costs and coinsurance amounts.
There's growing net price pressure in immunology and other specialty markets, he said.
Branded drug makers are looking to become more specialized and focus more on orphan drugs while also facing a backlash against price increases.
And generic price deflation will affect both wholesalers as well as generic manufacturers, both of whom are turning to purchasing alliances.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More